



ACN 010 126 708

ASX Release
14 June 2018

Implementation of Scheme of Arrangement and resignation and appointment of directors

Adelaide, 14 June 2018: RHS Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to announce that the scheme of arrangement between RHS and its shareholders (“Scheme”) has today been implemented. Implementation follows approval of the Scheme by RHS shareholders at the Scheme meeting held on 22 May 2018 and by the Federal Court of Australia on 29 May 2018.

All RHS shares have been transferred to PerkinElmer Holdings Pty Ltd (**PerkinElmer Australia**), being a wholly owned subsidiary of PerkinElmer, Inc., in consideration for \$0.28 in cash per fully paid RHS share. All RHS options were also transferred to PerkinElmer Australia and then cancelled with effect from implementation of the Scheme.

The Scheme Consideration, comprising \$0.28 in cash per fully paid RHS share, will be issued today to RHS shareholders who hold RHS shares on the record date, being 6.30pm (Adelaide time) on 6 June 2018.

RHS also wishes to announce the resignation of Dr David Brookes, Johnathon Matthews, Sue MacLeman and Dr Colin Matthews (alternate for Johnathon Matthews) from the Board of Directors each with effect from today, 14 June 2018. Ray Ridge has also resigned as company secretary of RHS with effect from today. The Board would like to thank David Brookes, Johnathon Matthews, Sue MacLeman, Colin Matthews and Ray Ridge for the valuable contribution they have provided to RHS.

RHS also wishes to announce that John Healy, Daisy AuYeung Yik Yan and Oksana Mugalimova have been appointed as directors of RHS and Oksana Mugalimova as company secretary of RHS, each with effect from today, 14 June 2018.

An application to remove RHS from the Official List will be made shortly.

For further information please contact:

Dr Michelle Fraser
CEO and Managing Director
Tel: (+61 8) 8152 9348
michelle.fraser@rhsc.com.au

About RHS

RHS is a developer of advanced single cell genomic technologies focussed on improving health and research outcomes, based on deep technical experience in the field. DOPlify® is a platform product for whole genome amplification (WGA) of single or small numbers of cells. DOPlify® is applicable to the global Next Generation Sequencing (NGS) market. PG-Seq™, RHS' NGS workflow and EmbryoCollect®, RHS' microarray workflow, both incorporate DOPlify® and have been specifically designed for the genetic screening of IVF embryos.